Xponance, Inc. Mirati Therapeutics, Inc. Transaction History

Xponance, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$39.16 - $88.71 $162,983 - $369,211	-4,162 Closed	0 $0
Q1 2022 Apr 20, 2022	BUY	$75.82 - $150.97 $18,955 - $37,742	250 Added 6.39%	4,162 $342,000
Q4 2021 Jan 31, 2022	BUY	$132.01 - $190.29 $19,801 - $28,543	150 Added 3.99%	3,912 $574,000
Q3 2021 Nov 05, 2021	SELL	$132.13 - $177.45 $8,852 - $11,889	-67 Reduced 1.75%	3,762 $666,000
Q2 2021 Aug 12, 2021	BUY	$144.0 - $179.73 $551,376 - $688,186	3,829 New	3,829 $618,000

Q1 2021 May 10, 2021	SELL	$158.92 - $221.61 $192,928 - $269,034	-1,214 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$162.05 - $240.27 $196,728 - $291,687	1,214 New	1,214 $267,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

Stay updated on Xponance, Inc. with notifications on news.